Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 1;57(5):436.
doi: 10.3390/medicina57050436.

Donor-Derived Cell-Free DNA (ddcf-DNA) and Acute Antibody-Mediated Rejection in Kidney Transplantation

Vishal Jaikaransingh  1 , Pradeep V Kadambi  1
Affiliations
Review

Donor-Derived Cell-Free DNA (ddcf-DNA) and Acute Antibody-Mediated Rejection in Kidney Transplantation

Vishal Jaikaransingh et al. Medicina (Kaunas). .

Abstract

Monitoring kidney transplant recipients for evidence of allograft rejection is essential to lower the risk of graft loss. The traditional method relies on serial checks in serum creatinine with a biopsy of the allograft if dysfunction is suspected. This is invasive, labor-intensive and costly. As such, there is widespread interest in the use of biomarkers to provide a noninvasive approach to detecting allograft rejection. One such biomarker is donor-derived cell-free DNA (ddcf-DNA). Here, we review the methodology for the determination of the amount/fraction of ddcf-DNA, evaluate the available data of its use in kidney transplantation and render an opinion in the clinical decision-making of these patients.

Keywords: antibody-mediated rejection; cell-free DNA; donor-derived cell-free DNA; kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650. - PubMed
    1. Lo Y.D., Tein M.S., Pang C.C., Yeung C.K., Tong K.-L., Hjelm N.M. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet. 1998;351:1329–1330. doi: 10.1016/S0140-6736(05)79055-3. - DOI - PubMed
    1. Zhang J., Tong K.L., Li P.K., Chan A.Y., Yeung C.K., Pang C.C., Wong T.Y., Lee K.C., Lo Y.M. Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: Urinary DNA chimerism. Clin. Chem. 1999;45:1741–1746. doi: 10.1093/clinchem/45.10.1741. - DOI - PubMed
    1. Bloom R.D., Bromberg J.S., Poggio E.D., Bunnapradist S., Langone A.J., Sood P., Matas A.J., Mehta S., Mannon R.B., Sharfuddin A., et al. Cell-Free DNA and Active Rejection in Kidney Allografts. J. Am. Soc. Nephrol. 2017;28:2221–2232. doi: 10.1681/ASN.2016091034. - DOI - PMC - PubMed
    1. Stites E., Kumar D., Olaitan O., Swanson S.J., Leca N., Weir M., Bromberg J., Melancon J., Agha I., Fattah H., et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. Arab. Archaeol. Epigr. 2020;20:2491–2498. doi: 10.1111/ajt.15822. - DOI - PMC - PubMed